Day 1: Wednesday, September 23
Day 1: Wednesday, September 23
08:00 - 09:0060 mins
Morning Registration & Breakfast
09:00 - 09:055 mins
KEYNOTE PLENARY
Obesity Science & Innovation Welcome
- Kaitlin Dailey - Senior Conference Producer, Obesity Science & Innovation, Informa Connect
09:05 - 09:2015 mins
KEYNOTE PLENARY
Keynote Opening Address
09:20 - 10:0545 mins
KEYNOTE PLENARY
Keynote Panel: Redefining Healthy Weight-Loss: Innovations, Challenges, and Future Opportunities
- Raj Reddy - CEO, Canary Cure
- Steffen-Sebastian Bolz - CSO, Aphaia Pharma AG
- Philip Larsen - CEO, Antag Therapeutics
- Jonathan Pappas - SVP, Head of Media Relations, LifeSci Communications
10:05 - 10:5045 mins
KEYNOTE PLENARY
Keynote Panel: Partnerships In Focus - Essential Pharma and Investor “Must Haves”
- Robrecht Thoonen - Senior Director External Innovation, Diabetes, Obesity & Cardiometabolic, Eli Lilly
- Laura Holberger - Associate Director, R&D External Innovation Partners, Novo Nordisk
- Tari Suprapto - VP Search and Evaluation, Zealand Pharma
- Luba Greenwood - CEO, Mwyngil Therapeutics
- Helena Correia - CEO, Boston Biodevelopment
10:50 - 11:2030 mins
Morning Refreshment Break
11:20 - 11:4525 mins
IN FOCUS: RNA-BASED THERAPIES
Leveraging siRNA Therapeutics to Target the Endocannabinoid and Energy Expenditure Systems for Sustainable Weight Loss and Rare Pediatric Obesity Solutions
- Raj Reddy - CEO, Canary Cure
11:45 - 12:1025 mins
IN FOCUS: RNA-BASED THERAPIES
Resetting gene networks with novel siRNA to treat obesity and T2D
- Janine Sengstack - CSO, Junevity
12:10 - 12:3525 mins
IN FOCUS: RNA-BASED THERAPIES
Reserved For Partner
12:35 - 13:0025 mins
IN FOCUS: RNA-BASED THERAPIES
siRNA-Mediated ACVR1C Suppression in Adipose Tissue - Phase 1 Insights
- Lucas BonDurrant - Principle Scientist, Alnylam
13:00 - 14:2080 mins
Lunch Break
14:20 - 14:4525 mins
CLINCAL INSIGHTS INCRETIN-BASED THERAPIES
Amylin Pharmacology - Enhancing Patient Experience
- Myung Shin - VP Biology, Discovery Research, Zealand Pharma
14:45 - 15:1025 mins
CLINCAL INSIGHTS INCRETIN-BASED THERAPIES
NA-931: A Quadruple Receptor Agonist for Weight Loss Therapy Without Muscle Loss
- Lloyd Tran - CEO, Biomed Industries
15:10 - 15:3525 mins
CLINCAL INSIGHTS INCRETIN-BASED THERAPIES
Reserved For Partner
- Jeremie Boucher - SVP, Head of Metabolic Disease, Evotec
15:35 - 16:0025 mins
CLINCAL INSIGHTS INCRETIN-BASED THERAPIES
Progressing A Small Molecule THR-β Agonist, ECC4703, For MASH & Weight Management
16:00 - 16:3030 mins
Afternoon Refreshment Break
16:30 - 16:5525 mins
SPOTLIGHT: PEDRIATRIC & ADOLESCENT OBESITY
Therapeutics for Pediatric & Adolescent Obesity: A Clinicians Perspective Current Gaps and Future Opportunity
- Sonali Malhorta Singh - Clinical Development Medical Director, AstraZeneca
16:55 - 17:2025 mins
IN FOCUS: ADIPOSE-TARGETED THERAPIES
Unlocking Brown Adipose Stem Cell Differentiation with a Once-daily Small Molecule
- Olivier Boss - Chief Scientific Officer and Founder, Energesis Pharmaceuticals
17:20 - 17:4525 mins
IN FOCUS: ADIPOSE-TARGETED THERAPIES
FFA-Mediated Energy Expenditure Acceleration with Mitochondria-Targeting Small Molecules
- Anton Petrov - COO, Mitotech
17:45 - 19:1590 mins
Networking Drinks Reception
* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。